Background: MicroRNAs (miRNAs) consist of a group of small noncoding RNAs that partially regulate gene expression. We investigated the expression patterns of commonly deregulated miRNAs in Crohn's disease (CD) and ulcerative colitis (UC) in peripheral blood samples of inflammatory bowel disease patients. Patients and methods: This study consisted of 128 CD and 88 UC patients, as well as 162 healthy controls. The expression patterns of the miRNA species were quantitatively assayed using reverse transcription and real-time RT-PCR. Stem-loop complementary DNAs (cDNAs) were synthesized using looped reverse transcription primers specific for each miRNA. Results: miR200c, and miR-532-3p were expressed at significantly higher levels in the blood from patients with CD compared with the healthy controls. No significant differences were observed when the CD patients were classified according to disease location and phenotype. In the UC cases three miRNAs (miR-16, miR-21, miR-28-5p, miR-151-5p, miR-155 and miR-199a-5p) were significantly increased compared to healthy controls. miR-155 was the most highly expressed of the UC-associated miRNA in blood samples. A v a i l a b l e o n l i n e a t w w w . s c i e n c e d i r e c t . c o m
Introduction
Inflammatory bowel disease (IBD), encompassing the chronic relapsing inflammatory disorders Crohn's disease (CD) and ulcerative colitis (UC), is thought to result from an inappropriate and continuing inflammatory response to commensal microbes in a genetically susceptible host. 1 However, CD and UC exhibit distinct clinical, genetic and immunologic characteristics that indicate that CD and UC are different disease types with overlapping characteristics. [1] [2] [3] [4] In addition to distinct genetic risk factors for CD and UC, genome-wide association studies have identified a multitude of common ones, 5 while mRNA expression and proteomics studies have demonstrated that CD and UC differ in various aspects. 6, 7 Despite the intense research, the regulation of inflammatory gene expression is not fully understood. Understanding how these genes are regulated may lead to the development of effective therapies targeting several key pathways involved in IBD.
Gene expression is partially regulated by microRNAs (miRNAs), a group of small (~18-24 nucleotide), noncoding RNAs. 8 The biogenesis of miRNA remains still unknown but it is quite clear that it is carried out in a multi-step process, from longer pre-miRNAs in the nucleus, to mature mi-RNAs in the cytoplasm. The maturation of miRNA occurs via a series of steps and two main RNase III endonucleases (Drosha and Dicer) are involved in this process. The inhibitory function of mature miRNA is mediated by two main pathways: the degradation of mRNA by binding of miRNA to the 3′ untranslated region of mRNA, or direct repression of the translational process. A number of biological processes are regulated by miRNA, including cell survival, differentiation and homeostasis; furthermore, specific miRNAs regulate the differentiation of intestinal epithelial cells. 9 While the majority of studies are focused on the role of these molecules in the development of cancer, their impact on autoimmune diseases and especially IBD is much less studied. It has been suggested that the critical function of these small RNAs is to contribute to the establishment of immunological homeostasis at mucosal sites. 10 The loss of all of the intestinal miRNA results in impaired barrier function and inflammation similar to IBD. 11 Nevertheless, little is known regarding the function of miRNA in IBD. Wu et al. 12 reported significant changes in 11 miRNAs in UC tissues when compared with normal controls. The same scientists have also investigated ileal and colonic miRNA expression, resulting in the identification of several miRNAs whose levels are altered in CD. 13 Additionally, to date only two studies have explored circulating miRNAs within the scope of IBD.
14, 15 Wu et al. 14 indentified peripheral blood cell miRNAs capable to distinguish adult patients with CD and UC and Zahm et al. 15 identify 11 CD-associated serum miRNAs. Thus, the use of serum or plasma miRNAs may prove useful noninvasive tools for the diagnosis or differentiation of IBD. However, there is a lot remaining to be understood in the involvement of miRNAs in IBD pathogenesis.
In the present study, we investigated the expression patterns of commonly deregulated miRNAs in CD and UC in peripheral blood samples of IBD patients and assessed their clinical use.
Materials and methods

Study subjects
This study consisted of 128 patients with CD, 88 patients with primary UC and 162 healthy controls. The diagnosis of either CD or UC was based on standard clinical, endoscopic, radiological, histological criteria, and colonoscopy.
2 UC cases were phenotyped according to the Montreal Classification systems. Before commencement of the study, the Ethics Committee at the participating centers approved the recruitment protocols. All participants were informed of the study.
RNA isolation, complementary DNA synthesis and quantification
Blood samples were collected on the PAXgene blood RNA tubes (PreAnalytiX GmbH, Switzerland). miRNA was purified using the mirVana™ miRNA Isolation Kit (Applied BioSystems, Foster City, CA) according to manufacturer instructions. The expression patterns of the miRNA species tested and a housekeeping gene, U6sn, were quantitatively assayed using reverse transcription and real-time RT-PCR. Stem-loop complementary DNAs (cDNAs) were synthesized using looped reverse transcription primers specific for each miRNA. All the materials were purchased by Exiqon (Exiqon, Vedbaek, Denmark). In realtime PCR assays forward primers specific for each cDNA and a reverse primer universal for all cDNAs were used. We examined the expression of miR-16, miR-19b, miR-21, miR-23a, miR-28-5p, miR-29a, miR-31, miR-106a, miR-107, miR-126, miR-143, miR-151-5p, miR-155, miR-191, miR-199a-5p miR-200c, miR-223, miR-362-3p, miR-422b and miR-532-3p. All samples were analyzed twice to confirm reproducibility.
Data normalization and statistical analysis
miR-16, miR-19b, miR-21, miR-23a, miR-28-5p, miR-29a, miR-31, miR-106a, miR-107, miR-126, miR-143, miR-151-5p, miR-155, miR-191, miR-199a-5p miR-200c, miR-223, miR-362-3p, miR-422b and miR-532-3p and U6sn were reliably amplified in tested samples. Amplified miRNAs showed specific melting temperature, confirming the accuracy and specificity of the method used. Real-time quantitative RT-PCR was conducted on an ABI Prism 7700 apparatus (Applied Biosystems). Data were analyzed with the ABI Prism 7700 SDS software (Applied Biosystems). The expression of each miRNA was normalized to U6sn RNA internal control. The levels of miRNAs expression were normalized after subtracting the C t value of the U6sn RNA internal control from that of each miRNA C t value for samples (ΔC t =|C tmiRNA (samples) − C tU6sn |). In order to compare the levels of miRNA expression between the samples tested, the ΔΔC t value was determined using the formula [ΔΔC t = ΔC tmiRNA (sample A) − ΔC tmiRNA (sample B)]. Then, the relative level of miRNA in cancer samples was compared to normal samples by setting the miRNA expression in normal samples value to 1 and determining the fold change in expression against this value using the following formula 2
ΔΔCt . Mann-Whitney U test was performed to compare differences in miRNA levels between patients and controls. Correlations between miRNAs expression and clinicopathological parameters were also statistically analyzed. Probability values of b0.05 were considered significant.
Results
miRNAs were extracted from the peripheral blood of patients with active CD, active UC and healthy control samples. The clinical characteristics of each patient group are summarized in Table 1 . The miR-16, miR-19b, miR-21, miR-23a, miR-28-5p, miR-29a, miR-31, miR-106a, miR-107, miR-126, miR-143, miR-151-5p, miR-155, miR-191, miR-199a-5p miR-200c, miR-223, miR-362-3p, miR-422b and miR-532-3p were selected because their expression was altered in previous studies on inflammatory disorders, including IBD. 14, 16 Differences in individual circulating miRNA levels between groups were identified.
Regarding the CD cases, miR-16, miR-23a, miR-29a, miR106a, miR-107, miR-126, miR-191, miR-199a-5p, miR-200c, miR-362-3p and miR-532-3p were expressed at significantly higher levels in the blood from patients with CD compared with the healthy controls. The expression levels were presented in Table 2 . No circulation miRNAs were significantly decreased in patients with CD. When the impact of location was examined miRNA expression between the ileal, colonic disease or ileocolitis group of patients did not significantly differ. No significant differences were observed when the CD patients were classified according to disease phenotype.
Concerning the UC cases, three miRNAs (miR-16, miR-21, miR-28-5p, miR-151-5p, miR-155 and miR-199a-5p) were significantly increased compared to healthy controls (Table 2) . miR-155 was the most highly expressed of the UC-associated miRNA in blood samples. No miRNAs were significantly decreased in the peripheral blood of patients with UC. Our results suggest that several miRNAs could distinguish CD from UC by real-time PCR.
Discussion
The differential expression of circulating miRNAs and their role in IBD has not been broadly studied. Wu et al. 12 was the first group that reported the differential expression of miRNA in the mucosa of patients with active UC tissues compared to healthy tissues. The miRNA expression was also different in healthy controls compared to quiescent UC patients. Wu et al. 13 demonstrated that ileum and sigmoid colon tissues obtained from CD patients expressed distinct miRNAs. While differential miRNA expression in the patients' tissues might yield insight into the complex mechanisms underlying the IBD pathogenesis, the need to collect biopsies for miRNA expression profile analysis renders it an invasive diagnostic method. Thus, there is pressing need for noninvasive biomarkers to predict prognosis and treatment response and circulating biomarkers are attractive because Fold change is relative to controls and presented as mean ± SD. a P b 0.05.
blood samples are easy to collect. Recently, detection of miRNAs in the blood has been extended to immune disorders such as systemic lupus erythematosus and rheumatoid arthritis. 17, 18 Regarding IBD, Wu et al. 14 in an adult population and Zahm et al. 15 in a pediatric population presented the first evidence that peripheral blood miRNAs can distinguish active IBD subtypes form each other and healthy controls.
In the present study, using real-time PCR, we identified that 11 miRNAs significantly increased in CD blood samples and 6 miRNAs were elevated in UC blood samples compared to healthy controls. Our results are consistent with previous findings of miRNAs expression in IBD blood or/and tissue samples. 9, 16 Of the miRNAs tested, miR-16 and miR-199a-5p were elevated in both CD and UC as compared to healthy controls. Concerning CD, our results are in agreement with the previous findings by Wu et al. 14 and Zahm et al. 15 Furthermore, miR-16 was found to be elevated in peripheral blood mononuclear cells obtained from patients with rheumatoid arthritis, 19 and miR-199a-5p in patients with systemic lupus erythematosus. 20 These observations support that miR-16 and miR-199-5a might be implicated in inflammation process common to both IBD and other autoimmune disorders.
However, our findings reveal circulating miRNAs uniquely present at either at CD or UC, indicating that circulating miRNAs can be used to distinguish the two diseases. Four of the CDassociated miRNAs (miR-29a, miR-126, miR-191 and miR200c), and two of the UC-associated miRNAs (miR-21 and miR-155) were previously identified as also differentially expressed in IBD biopsy tissues, indicating that circulating miRNAs might reflect miRNA expression changes in the diseased tissues. 21 Consistent with previous studies, we observed distinct miRNAs expression between CD and UC. The differential miRNA expression between CD and UC is expected since these IBD subtypes differ in their associated T-and B-cell subtypes. Of all IBDassociated miRNAs tested in the present study, several miRNAs have been implicated in the regulation of inflammatory disorders. Specifically, miR-16 as previously mentioned was found to be upregulated in rheumatoid arthritis. 19 It has also been suggested that miR-21 expression in memory T-lymphocytes and miR-21 activation though T-cell receptor (TCR) stimulation negatively modulated TCR signaling. Thus, the regulation of miR-21 might be involved in the differentiation of T cells in the immune system. 22 MiR-106 was found to be upregulated in psoriasis. 23 Regarding miR-155, that has been shown to be a key factor for innate and acquired immune responses. MiR-155 is required for T-cell differentiation and function, germinal center B-cell responses and responses to bacterial and viral infections. 24 It can be hypothesized that the observed overlap of miRNAs among different inflammatory and/or autoimmune disorders suggests that these miRNAs function as key regulators of innate and adaptive immune mechanisms by regulating immune-related targets mRNAs. Since there are limited studies on the role of miRNA in IBD, further studies are needed to understand the precise role of immune-associated miRNAs and to confirm the ability of circulating miRNAs to distinguish IBD subtypes, as well as to determine the correlation of miRNAs with disease severity and outcome.
Collectively, our results further highlight the putative role of miRNAs as contributors to IBD pathogenesis. They may help develop new non-invasive biomarkers to distinguish UC and CD.
